2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

5699 Aldoa-driven metabolic adaptation promotes invasive phenotypes in extramedullary multiple myeloma

Yajun Wang, PhD, Jiangxue Hou, MD2, Xu Ji, PhD3, juan wang4, Yaomei Wang, PhD5, quande Lin, PhD6
1 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
2 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
3 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
4 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
5 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
6 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China

Introduction:
Extramedullary multiple myeloma (EMM) is an aggressive disease phenotype associated with poor clinical outcomes. Adaptation to hypoxic and metabolically stressful microenvironments is considered an important biological feature underlying extramedullary dissemination; however, the metabolic regulators involved in this process remain incompletely characterized. In single-cell transcriptomic profiles from five paired bone marrow and extramedullary lesions, ALDOA was preferentially expressed in extramedullary plasma cells and enriched in stress-response and EMT-related plasma-cell states. This study aimed to define the role of ALDOA in metabolic adaptation and invasive phenotypes in EMM.

Methods:
Patient-derived single-cell transcriptomic profiles, bulk CD138+ plasma-cell transcriptomes, and public myeloma datasets were integrated to evaluate the clinical and biological relevance of ALDOA. An ALDOA-overexpressing RPMI8226 cell model was established for functional characterization of tumor growth, migration, metabolic adaptation, mitochondrial function, and cell-cycle regulation. RNA sequencing, qRT-PCR validation, and untargeted metabolomics were performed to identify ALDOA-associated molecular and metabolic alterations.

Results:
ALDOA was highly expressed in extramedullary plasma cells and associated with hypoxia-, stress-response-, and EMT-related transcriptional programs. Bulk transcriptomic and public dataset analyses further demonstrated elevated ALDOA expression in CD138+ plasma cells from patients with extramedullary involvement, increased ALDOA expression during disease progression, and an association with patient survival. Functionally, ALDOA overexpression enhanced RPMI8226 cell growth under nutrient-deprived conditions and promoted migration. Glucose uptake analysis revealed a context-dependent metabolic phenotype: ALDOA-overexpressing cells exhibited increased glucose uptake under standard culture conditions but reduced glucose uptake after acute glucose deprivation, suggesting adaptive metabolic remodeling rather than a simple increase in glucose influx. Consistently, ALDOA overexpression resulted in increased extracellular lactate accumulation (~23.7%) with reduced intracellular lactate levels, indicating altered lactate distribution and enhanced lactate efflux. JC-1 staining demonstrated mitochondrial membrane potential loss following ALDOA overexpression. CFSE and cell-cycle analyses showed increased cumulative cell division accompanied by G1 accumulation and reduced S-phase proportion, suggesting altered cell-cycle dynamics. Integrated transcriptomic, qRT-PCR, and metabolomic analyses revealed coordinated remodeling of central carbon metabolism, mitochondrial energy metabolism, nucleotide metabolism, membrane lipid metabolism, phosphoinositide signaling, cytoskeletal organization, and stress-adaptation programs. 

Conclusions:
ALDOA is enriched in extramedullary, hypoxic, stress-responsive, and EMT-associated myeloma plasma cells and is linked to extramedullary involvement, disease progression, and adverse clinical outcome. Functional and multi-omics analyses indicate that ALDOA promotes metabolic adaptation and invasive behavior by reshaping lactate metabolism, mitochondrial homeostasis, membrane lipid metabolism, and cytoskeletal programs. These findings identify ALDOA as a potential regulator of extramedullary progression and a candidate therapeutic target in multiple myeloma.

Yajun Wang, PhD: No relevant conflicts of interest to declare.